Brainstorm announces positive topline data in phase 2 study evaluating nurown® as a treatment for progressive ms

New york, march 24, 2021 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the company's phase 2 trial evaluating three repeated administrations of nurown® (msc-ntf cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (ms). the study achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.
BCLI Ratings Summary
BCLI Quant Ranking